Biohaven Ltd. (BHVN) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

34/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

65

Gaining

Sentiment

44

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Vladimir Coric
Listed since: Sep 23, 2022
Employees: 274

Market position

Day range

Current $13.755

$13.62$13.97

52-week range

Current $13.755

$7.48$18.566

Open: $13.95
Previous close: $13.85
Volume: 196.73K; 0.08× average
Average volume: 2.57M; Average daily volume
Market cap: 2.07B USD
Beta: 3.16; Market reference 1
50-day average: $14.4514; -4.82% below average
200-day average: $11.3798; +20.87% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.27B USD
P/E (TTM): -2.98×
P/B (TTM): 170.46×
P/S (TTM): 0×
EV / EBITDA: -1.75×
Earnings yield: -60.80%
Free cash flow yield: -50.21%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -1418.85%
Return on assets: -163.66%
Return on invested capital: -218.41%

Financial health

Debt / equity: 24.3×
Current ratio: 3.18×

Financial statements

Income trends

Operating income

−745.38M USD+15.79%

Net income

−738.82M USD+12.71%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	4.14M USD	—	—	—	—
Gross profit	−4.14M USD	—	—	—	—
Research and development	635.07M USD	795.87M USD	373.28M USD	437.07M USD	181.49M USD
Selling, general, and administrative	106.17M USD	89.24M USD	62.77M USD	130.86M USD	37.41M USD
Operating expenses	741.24M USD	885.11M USD	436.05M USD	567.93M USD	218.9M USD
Interest income	14.59M USD	21.33M USD	17.73M USD	—	—
Depreciation and amortization	9.92M USD	7.86M USD	6.91M USD	1.39M USD	1.39M USD
Operating income	−745.38M USD	−885.11M USD	−436.05M USD	−567.93M USD	−218.9M USD
Net income	−738.82M USD	−846.42M USD	−408.17M USD	−570.28M USD	−213.8M USD